NCCN Pleural Mesothelioma Guidelines 2025–2026: 4 Evidence Categories Explained

The NCCN Guidelines for malignant pleural mesothelioma rank every recommended treatment by a category of evidence — and in the 2025–2026 framework, only one first-line regimen carries the top rating. Nivolumab plus ipilimumab is the lone Category 1 systemic therapy for eligible patients with unresectable disease, a designation built on five-year survival data showing 14% of patients alive at five years versus 6% on chemotherapy [1][4].

For patients and families researching how a recommended treatment fits the broader evidence base, the Mesothelioma Treatment Options reference at WikiMesothelioma [10] and the firm's overview of the latest mesothelioma treatment advances provide companion context to the guideline framework described below.

What Are the NCCN Guidelines for Pleural Mesothelioma?

• The NCCN Guidelines are an evidence-based treatment standard developed by oncology specialists from leading U.S. cancer centers and updated as new trial data emerge [1]
• Every recommendation is assigned one of four categories of evidence and consensus, from Category 1 (strongest) to Category 3 (major disagreement) [2]
• Nivolumab plus ipilimumab is the Category 1 first-line systemic option for unresectable disease, regardless of histology [1][3]
• Histology — epithelioid versus sarcomatoid or biphasic — is the primary driver of first-line treatment selection [8]
• Pemetrexed plus platinum chemotherapy remains a recommended first-line option, anchored by the EMPHACIS trial [5]
• Surgery is reserved for clinically early-stage epithelioid tumors at experienced, high-volume centers [1][6]
• Pleurectomy/decortication (P/D) is preferred over extrapleural pneumonectomy (EPP) when an operation is performed [1]
• PD-L1 expression, tumor mutational burden, and microsatellite instability are not used to select mesothelioma therapy [8]
• The guidelines integrate the 2024 MARS2 surgical trial and the 2026 CheckMate 743 five-year update into current recommendations [4][6]
• NCCN recommendations are widely used by treating physicians, cancer centers, and insurers to define the standard of care [9]

Malignant pleural mesothelioma is a rare, aggressive cancer of the lining of the lungs, caused almost exclusively by asbestos exposure. Because it is uncommon, treatment decisions benefit from a structured, evidence-graded framework rather than physician-by-physician judgment. The NCCN Guidelines provide that framework, and the Pleural Mesothelioma overview at WikiMesothelioma [11] summarizes how the disease is classified before treatment begins.

What Do the NCCN Categories of Evidence Mean?

The category system is the foundation of how the guidelines communicate the strength behind each recommendation. The four categories are defined as follows [2]:

Category	Evidence level	Panel consensus
Category 1	High-level evidence	Uniform NCCN consensus that the intervention is appropriate
Category 2A	Lower-level evidence	Uniform consensus (≥85% panel support)
Category 2B	Lower-level evidence	Consensus from ≥50% to <85% of the panel
Category 3	Any level of evidence	Major NCCN disagreement that the intervention is appropriate

Across all cancers, the majority of NCCN recommendations are Category 2A — meaning they reflect uniform expert agreement but rest on lower-level evidence rather than large randomized trials [2]. A Category 1 designation is comparatively rare, which is part of what makes the nivolumab-plus-ipilimumab rating in mesothelioma notable.

"When families ask me why one regimen was recommended over another, the category of evidence is the clearest answer I can give them. A Category 1 rating means the highest level of trial data and complete agreement among the experts who write the guideline. In a disease as rare as mesothelioma, that combination is unusual — and it tells you the recommendation is built on something solid."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Which Mesothelioma Treatments Does NCCN Rank as Category 1?

In the current pleural mesothelioma guideline, nivolumab plus ipilimumab is the first-line systemic therapy that carries the Category 1 designation for eligible patients with unresectable disease, regardless of cell type [1][3]. The rating rests on the CheckMate 743 phase 3 trial, which compared dual immunotherapy against platinum-based chemotherapy as initial treatment.

The initial CheckMate 743 results, published in The Lancet in 2021, reported a median overall survival of 18.1 months on nivolumab plus ipilimumab versus 14.1 months on chemotherapy, with a hazard ratio for death of 0.74 [3]. The five-year follow-up, published in the Journal of Clinical Oncology in 2026, confirmed a durable advantage [4]:

Outcome	Nivolumab + Ipilimumab	Chemotherapy
Median overall survival	18.1 months	14.1 months
5-year overall survival (all patients)	14%	6%
5-year overall survival (non-epithelioid)	12%	1%

Pemetrexed plus platinum chemotherapy — the regimen established by the EMPHACIS trial in 2003, which reported a median survival of 12.1 months on the doublet versus 9.3 months on cisplatin alone — remains a recommended first-line option in the guideline [5]. Pembrolizumab combined with pemetrexed and platinum chemotherapy became a recommended option after its FDA approval in September 2024, based on the KEYNOTE-483 trial [7]. Among these, nivolumab plus ipilimumab is the regimen that holds the Category 1 rating.

How Does NCCN Choose First-Line Therapy by Cell Type?

Mesothelioma is divided into three histologic subtypes — epithelioid, sarcomatoid, and biphasic (a mixture of the two). In the NCCN framework, this cell type is the single most important factor in selecting first-line systemic therapy [8].

Histology	Preferred first-line approach	Rationale
Sarcomatoid / biphasic (non-epithelioid)	Immunotherapy (nivolumab + ipilimumab)	Largest survival advantage of immunotherapy over chemotherapy in these subtypes
Epithelioid	Immunotherapy or pemetrexed-based chemotherapy	Both approaches are acceptable; selection considers patient factors and preference

This histology-driven logic reflects one of the clearest findings in the CheckMate 743 data: the survival benefit of immunotherapy over chemotherapy is largest in non-epithelioid disease, where five-year survival reached 12% on immunotherapy versus just 1% on chemotherapy [4]. Notably, the guideline does not rely on PD-L1 expression, tumor mutational burden, or microsatellite instability to choose mesothelioma therapy — biomarkers that guide treatment in many other cancers but have not proven decisive here [8].

What Does NCCN Recommend for Mesothelioma Surgery?

Surgery has long been one of the most debated areas in mesothelioma care, and the guideline position has tightened considerably. The current recommendation reserves an operation for carefully selected patients with clinically early-stage (node-negative) epithelioid tumors, treated at experienced, high-volume mesothelioma centers [1][6].

That narrowing was reinforced by the MARS2 phase 3 trial, published in The Lancet Respiratory Medicine in 2024, which tested whether adding extended pleurectomy/decortication to chemotherapy improved survival [6]. In its unselected trial population, the surgical arm had worse two-year survival, more serious adverse events, and worse quality of life than chemotherapy alone. The result did not eliminate surgery from the guideline, but it clarified that an operation benefits only a narrow group rather than most patients.

When surgery is performed, the guideline prefers pleurectomy/decortication (P/D) — a lung-sparing procedure that removes the diseased pleural lining — over extrapleural pneumonectomy (EPP), the more radical operation that removes the entire lung [1]. The shift from EPP toward P/D reflects years of accumulating evidence that the lung-sparing approach carries lower operative risk in appropriately selected patients.

"The surgery conversation in mesothelioma has changed more than almost any other part of the guideline. After MARS2, the question is no longer whether a patient can have an operation — it is whether they are one of the narrow group who genuinely benefits, and whether they are at a center that performs enough of these procedures to do it safely. That is exactly the kind of decision where a second opinion at a specialized center is worth seeking."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How Does NCCN Structure the Overall Treatment Algorithm?

The guideline organizes mesothelioma care into a sequence that begins with confirming the diagnosis and stage. Accurate staging — described in the Mesothelioma Staging reference at WikiMesothelioma [12] — determines whether a tumor is potentially resectable, which in turn shapes every subsequent decision [9].

• Diagnosis and staging: Tissue biopsy confirms histology; imaging and surgical staging establish extent of disease
• Multidisciplinary evaluation: Medical oncology, thoracic surgery, radiation oncology, and pathology assess the case together before treatment selection
• Resectable, early-stage epithelioid disease: Surgery may be considered at a high-volume center, combined with systemic therapy
• Unresectable disease: First-line systemic therapy, with nivolumab plus ipilimumab as the Category 1 option and chemotherapy or pembrolizumab-based regimens as alternatives
• Later lines and supportive care: Additional systemic therapy, clinical trial enrollment, and palliative measures including management of pleural effusions

Because the National Cancer Institute's Mesothelioma Treatment (PDQ) summary for health professionals [9] mirrors much of this evidence base, patients and physicians often consult both the NCCN framework and the NCI summary when weighing options. The 2025 review of malignant pleural mesothelioma published in the Journal of Clinical Medicine provides additional context on how these recommendations evolved [8].

Why Do NCCN Guidelines Matter for Mesothelioma Patients and Families?

NCCN guidelines define the standard of care that oncologists, cancer centers, and insurers use to justify treatment decisions. For a rare cancer like mesothelioma, the gap between guideline-concordant care at an experienced center and care at a low-volume community hospital can be substantial, because center volume strongly predicts outcomes in uncommon cancers.

Understanding how the guidelines rank treatments gives patients and families a vocabulary for informed questions: why a particular regimen was recommended, what its category of evidence is, whether a second opinion at an NCI-designated center is warranted, and whether a clinical trial is an option. Families navigating a mesothelioma diagnosis can find background on treatment centers through the mesothelioma treatment centers reference at Mesothelioma.net [14], and educational and legal resources through Danziger & De Llano [13], a firm that has represented mesothelioma patients and families for decades.

Because the guideline is revised as new trial data emerge — the 2024 MARS2 results and the 2026 CheckMate 743 update both reshaped current recommendations — the framework under which a patient was treated can change within a single year. Staying informed about the current standard is part of how patients and families make sure the care they receive reflects the latest evidence.

References

1. [1] Stevenson J, Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines Insights: Mesothelioma: Pleural, Version 1.2024. Journal of the National Comprehensive Cancer Network. 2024;22(2):72–81. PMID: 38503043.
2. [2] National Comprehensive Cancer Network. NCCN Categories of Evidence and Consensus. NCCN.org. Accessed June 2026.
3. [3] Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375–386. PMID: 33485464.
4. [4] Scherpereel A, Baas P, Nowak AK, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026. PMID: 41734361.
5. [5] Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003;21(14):2636–2644. PMID: 12860938.
6. [6] Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. The Lancet Respiratory Medicine. 2024;12(6):457–466. PMID: 38740044.
7. [7] U.S. Food and Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma. FDA.gov. September 17, 2024.
8. [8] Cardillo G, Waller D, Tenconi S, Di Noia V, et al. Malignant Pleural Mesothelioma: A 2025 Update. Journal of Clinical Medicine. 2025;14(4):1124. PMID: 39941672.
9. [9] National Cancer Institute. Mesothelioma Treatment (PDQ) – Health Professional Version. Cancer.gov. Accessed June 2026.
10. [10] WikiMesothelioma. Mesothelioma Treatment Options. wikimesothelioma.com/Treatment_Options.
11. [11] WikiMesothelioma. Pleural Mesothelioma. wikimesothelioma.com/Pleural_Mesothelioma.
12. [12] WikiMesothelioma. Mesothelioma Staging. wikimesothelioma.com/Mesothelioma_Staging.
13. [13] Danziger & De Llano. Mesothelioma Lawyers. dandell.com.
14. [14] Mesothelioma.net. Mesothelioma Treatment Centers. mesothelioma.net/mesothelioma-treatment-centers.